Recent advances in targeted therapy for pancreatic adenocarcinoma

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with Kirsten rat sarcoma oncogene (90%), cyclin-dependent kinase inhibitor 2A (90%), and tumor suppressor 53 (75%–90%) being the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Yu-Ting, Yang, Wen-Wei, Niu, Ya-Ru, Sun, Yong-Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134207/
https://www.ncbi.nlm.nih.gov/pubmed/37123059
http://dx.doi.org/10.4251/wjgo.v15.i4.571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134207/
https://www.ncbi.nlm.nih.gov/pubmed/37123059
http://dx.doi.org/10.4251/wjgo.v15.i4.571

Ejemplares similares